Ronald A Morton

US Patent:

20040053425, Mar 18, 2004

Filed:

May 6, 2003

Appl. No.:

10/430509

Inventors:

Richard Link - Pikesville MD, US
Ronald Morton - Richmond TX, US
Brian Miles - Houston TX, US
Michael Simon - Houston TX, US

Assignee:

Baylor College of Medicine

International Classification:

G01N033/553

US Classification:

436/526000

Abstract:

Custom-engineered glucose oxidase fusion proteins, prepared by recombinant DNA techniques, are employed in a chip-based amperometric immunosensor. This on-chip assay provides quantitative measurement of analyte concentration in any fluid, including all body fluids. The system is designed to facilitate ease in swapping of molecular recognition components and can be rapidly adapted to measure the concentration of any peptide or protein for which a monoclonal antibody is available.

US Patent:

20040072263, Apr 15, 2004

Filed:

Apr 21, 2003

Appl. No.:

10/419438

Inventors:

Richard Link - Pikesville MD, US
Ronald Morton - Richmond TX, US
Brian Miles - Houston TX, US
Michael Simon - Houston TX, US

Assignee:

Baylor College of Medicine

International Classification:

G01N033/53
C12M001/34

US Classification:

435/007500, 435/287200

Abstract:

Custom-engineered glucose oxidase fusion proteins, prepared by recombinant DNA techniques, are employed in a chip-based amperometric immunosensor. This on-chip assay provides quantitative measurement of analyte concentration in any fluid, including all body fluids. The system is designed to facilitate ease in swapping of molecular recognition components and can be rapidly adapted to measure the concentration of any peptide or protein for which a monoclonal antibody is available.

US Patent:

20120077845, Mar 29, 2012

Filed:

Aug 23, 2011

Appl. No.:

13/215679

Inventors:

James T. DALTON - Lakeland TN, US
Mitchell S. STEINER - Germantown TN, US
Ronald A. MORTON - Memphis TN, US

International Classification:

A61K 31/137
A61P 5/26
A61K 31/4453
A61K 31/167
A61P 35/00

US Classification:

514331, 514622, 514617, 514655

Abstract:

The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.